BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Eyetech, Pfizer Go Before FDA Panel With Macugen
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Eyetech, Pfizer Go Before FDA Panel With Macugen
Aug. 27, 2004
By
Kim Coghill
No Comments
Eyetech Pharmaceuticals Inc. and partner Pfizer Inc. today are scheduled to present data supporting use of the potential blockbuster Macugen as a treatment for neovascular or wet age-related macular degeneration. (BioWorld Today)
BioWorld